ArticleCell2006
PPM1A functions as a Smad phosphatase to terminate TGFbeta signaling.
Article in Cell, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 248 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
248 citing papers in PubMed, 479 citations in OpenAlex.
- SCP4 dephosphorylates mitotic histone H3 to maintain chromosome stability.EMBO reports · 2026Article
- A Bifunctional T3SS-Effector Simultaneously Cleaves Host MAP Kinase and Inhibits PPM1A Phosphatase.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- PPM1A dysfunction aggravates DPN pathology through NF-κB/NLRP3/p-tau axis involving Schwann cell/DRG neuron crosstalk.Journal of translational medicine · 2026Article
- Phosphatases in tumor cell immune escape: a perspective based on the camouflage, coercion, cytoprotection.Frontiers in cell and developmental biology · 2026Review
- Melandryoside attenuates steatohepatitis and fibrosis by restoring PPM1A-mediated SMAD signaling termination.Frontiers in pharmacology · 2026Article
- Reticulophagy receptor FAM134C restrains BMP receptor signaling.The EMBO journal · 2025Article
- SLC7A11-AS1 contributes to prolonged activation of activin A/Smad signaling by suppressing PPM1A myristoylation in pancreatic cancer.British journal of cancer · 2025Article
- Sox5 controls the establishment of quiescence in neural stem cells during postnatal development.PLoS biology · 2025Article
- Suppression of TGF-β/SMAD signaling by an inner nuclear membrane phosphatase complex.Nature communications · 2025Article
- Beyond Tumors: The Pivotal Role of TRIM Proteins in Chronic Non-Tumor Lung Diseases.Journal of inflammation research · 2025Review
- Activin A promoted the anti-tumor effect of ActRIIACancer medicine · 2025Article
- Otilonium bromide ameliorates pulmonary fibrosis in mice through activating phosphatase PPM1A.Acta pharmacologica Sinica · 2025Article
- Review
- Protein phosphatase PP2Cα S-glutathionylation regulates cell migration.The Journal of biological chemistry · 2024Article
- Optimal performance objectives in the highly conserved bone morphogenetic protein signaling pathway.NPJ systems biology and applications · 2024Article
- Article
- TGF‑β/Smad signaling in chronic kidney disease: Exploring post‑translational regulatory perspectives (Review).Molecular medicine reports · 2024Review
- Genome, HLA and polygenic risk score analyses for prevalent and persistent cervical human papillomavirus (HPV) infections.European journal of human genetics : EJHG · 2024Article
- Advances and Challenges in Targeting TGF-β Isoforms for Therapeutic Intervention of Cancer: A Mechanism-Based Perspective.Pharmaceuticals (Basel, Switzerland) · 2024Review
- TGF-β signaling in health, disease, and therapeutics.Signal transduction and targeted therapy · 2024Review
188 more citing papers are in PubMed but not listed here.
Corrections and comments
- Expression of concern · 2016-09-08Concerns/Issues about Data · Investigation by Company/Institution · Investigation by Journal/Publisher · Manipulation of Results · No Further Action · Objections by Author(s) · Upgrade/Update of Prior Notice(s) · · There is an earlier EoC;
- Expression of concern · 2016-04-17Concerns/Issues about Data · Investigation by Company/Institution · Investigation by Journal/Publisher · Manipulation of Results · Objections by Author(s) · · There is a further Editorial Note;
- Commented on by
- Commented on by
- Commented on by
Authors and funding
14 authors at 4 institutions in 2 countries.
Funding
Abstract
TGFbeta signaling controls diverse normal developmental processes and pathogenesis of diseases including cancer and autoimmune and fibrotic diseases. TGFbeta responses are generally mediated through transcriptional functions of Smads. A key step in TGFbeta signaling is ligand-induced phosphorylation of receptor-activated Smads (R-Smads) catalyzed by the TGFbeta type I receptor kinase. However, the potential of Smad dephosphorylation as a regulatory mechanism of TGFbeta signaling and the identity of Smad-specific phosphatases remain elusive. Using a functional genomic approach, we have identified PPM1A/PP2Calpha as a bona fide Smad phosphatase. PPM1A dephosphorylates and promotes nuclear export of TGFbeta-activated Smad2/3. Ectopic expression of PPM1A abolishes TGFbeta-induced antiproliferative and transcriptional responses, whereas depletion of PPM1A enhances TGFbeta signaling in mammalian cells. Smad-antagonizing activity of PPM1A is also observed during Nodal-dependent early embryogenesis in zebrafish. This work demonstrates that PPM1A/PP2Calpha, through dephosphorylation of Smad2/3, plays a critical role in terminating TGFbeta signaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.